Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2014

Open Access 01-12-2014 | Poster presentation

PB.15. An audit of our benign surgical biopsy rate in the prevalent round for the reporting year 1 April 2012 to 31 March 2013

Authors: R Geach, E Kutt, A Valencia

Published in: Breast Cancer Research | Special Issue 1/2014

Login to get access

Excerpt

The NHSBSP has defined standards with regard to benign surgical biopsy rates. In the prevalent population, the minimum defined standard is <3.6/1,000 with a target of <1.8/1,000. At the Avon Breast Screening Unit we have been identified as outliers. …
Metadata
Title
PB.15. An audit of our benign surgical biopsy rate in the prevalent round for the reporting year 1 April 2012 to 31 March 2013
Authors
R Geach
E Kutt
A Valencia
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2014
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3722

Other articles of this Special Issue 1/2014

Breast Cancer Research 1/2014 Go to the issue

Poster presentation

PB.24. How does volumetric breast density change with time?

Poster presentation

PB.37. Does conventional imaging accurately predict the extent of disease in women with dense breasts? If so, does this have a significant impact on patient surgical outcome?

Poster presentation

PB.13. Impact on film reading of moving from analogue to digital screening: a service evaluation - South East Scotland Breast Screening Programme

Poster presentation

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?

Poster presentation

PB.12. Audit and root-cause analysis of classification 2 and 3 interval cancers

Poster presentation

PB.44. Do qualitative patterns of stiffness help differentiate benign from malignant breast masses of similar stiffness during shear wave elastography?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits